Last reviewed · How we verify
NCT01834950: HERBIN
Identification of Early Markers of Response and Resistance to Trastuzumab
NA trial testing Blood test in Untreated Human Epidermal Growth Factor Receptor-2(HER2)Positive Early Breast Cancer in 25 participants. Completed in 10 December 2017.
10 December 2017
Quick facts
| Lead sponsor | Gustave Roussy, Cancer Campus, Grand Paris |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | other |
| Enrollment | 25 |
| Start date | 27 March 2013 |
| Primary completion | 10 December 2017 |
| Estimated completion | 10 December 2017 |
| Sites | 1 location across France |
Drugs / interventions tested
- Blood test — full drug profile →
Conditions studied
- Untreated Human Epidermal Growth Factor Receptor-2(HER2)Positive Early Breast Cancer — all drugs for Untreated Human Epidermal Growth Factor Receptor-2(HER2)Positive Early Breast Cancer →
Sponsor
Gustave Roussy, Cancer Campus, Grand Paris — full company profile →
Who can join
18 and older, female only, with Untreated Human Epidermal Growth Factor Receptor-2(HER2)Positive Early Breast Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The study is a single arm prospective study, aiming at identifying biomarkers of early response to trastuzumab. It is a prognostic factor study recruiting all consecutive cases of HER-2 positive breast cancer eligible for a pre-operative treatment by trastuzumab, followed by breast conserving surgery. The investigators will study the association between the value of biomarkers measured at diagnosis and the Response Evaluation Criteria in Solid Tumors response (partial and complete response) using a logistic regression (main analysis).
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Concordance between HER-2 status determined by qPCR in Fine Needle Aspiration Cytology (FNAC) samples compared with IHC and FISH in Core Needle Biopsy (CNB) or surgical specimens in breast cancer patients.
Rodriguez C, Suciu V, Poterie A, Lacroix L, et al · · 2016 · cited 2× · PMID 27555543 · DOI 10.1016/j.molonc.2016.07.009
Verify or expand the search:
- PubMed search for NCT01834950
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Blood test
Trials testing the same drug.
- NCT06863974 — High-throughput Omic Technology for Identification of Biomarkers of Relapsing Acute Disseminated Encephalomyelitis in Im · NA · recruiting
- NCT07078435 — Innate Immunity, MIcrobiota and Inovative Treatments in Endometriosis · NA · not yet recruiting
- NCT05370300 — SNAPS Breast Cancer Patient Study Breast Cancer Patients · not yet recruiting
- NCT06820450 — Pilot Study to Characterize the Endometriosis Steroidome and Its Link to Endocrine Disruptors and Vaginal Dysbiosis · not yet recruiting
- NCT06999785 — Assessment of the Impact of Increased Production of Reactive Oxygen Species Produced During Repeated Sessions of Hyperba · NA · recruiting
Other Gustave Roussy, Cancer Campus, Grand Paris trials
Trials by the same sponsor.
- NCT07303387 — Efficacy and Safety of the Valemetostat in Patients With Selected Solid Tumors. · Phase 2 · not yet recruiting
- NCT07159451 — A Short-term Preoperative, Evaluating Activity and Safety of Elacestrant Monotherapy as Compared to Elacestrant + Ovaria · Phase 2 · recruiting
- NCT06781996 — A Study to Determine the Efficacy of a Digital Self-management Support Tool to Improve the Quality of Life During Adjuva · Phase 3 · recruiting
- NCT07016230 — Study Investigating Tarlatamab (AMG 757) in Patients With Metastatic/Locally Advanced Small-Cell Lung Cancer (SCLC) and · Phase 2 · recruiting
- NCT06902883 — Study on the Effectiveness and Comfort of Innovative Solutions for the Internal Transport of Patients in Wheelchairs in · Phase 2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT01834950 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Gustave Roussy, Cancer Campus, Grand Paris
- Last refreshed: 29 March 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01834950.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing